Macera Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Macera Therapeutics - overview
Established
2022
Location
Nanjing, Jiangsu, China
Primary Industry
Biotechnology
About
Based in Nanjing, China, and established in 2022, Macera Therapeutics is a biotechnology company that engages in the R&D of macrophage cell immunotherapy new drugs for tumors. Pingping Shen, the company's founder, served as a professor at Nanjing University. And Yijun Chen, the company's CEO, worked in Singapore Central Hospital, Esco Venture, and Broad Pharma (China), and has more than 10 experience in biotechnology. The company engages in the R&D of new drugs for tumors, and autoimmune diseases, adopting the CAR-Macrophage technology.
It also developed molecular editing and manipulation systems, IPSC-derived immune cell differentiation systems, ligand-receptor, and other information flow recognition and conduction technology platforms, which can edit the genes, identify the target antigens, and kill the tumor cells.
Current Investors
CDH Investments, Nanjing Jiangbei New Area Sci-Tech Investment Group, Tianjin Renai Group
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Healthcare IT, Oncology/Cancer Treatment, Pharmaceutical Research & Development, Medical Software
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.